Lipocine Inc (LPCN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Lipocine Inc (LPCN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH190476D
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Lipocine Inc (Lipocine) is a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company's products pipeline for men's health include LPCN 1021 and LPCN 1111; and for women's health include LPCN 1107. Its LPCN 1021 is an oral testosterone replacement therapy with positive topline, and LPCN 1111 is an oral testosterone product candidate. Lipocine offers LPCN 1107, an oral hydroxyprogesterone caproate product for prevention of preterm birth. The company develops patented technology based on lipidic compositions, which form optimal dispersed phase in the gastrointestinal environment for improved absorption of the insoluble drug. Its Lip'ral is a technology based on lipidic compositions that form optimal dispersed phase in the gastrointestinal environment. Lipocine is headquartered in Salt Lake City, Utah, the US.

Lipocine Inc (LPCN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Lipocine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Lipocine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Lipocine Inc, Pharmaceuticals & Healthcare, Deal Details 10

Merger 10

Marathon Bar And Lipocine Complete Reverse Merger Transaction 10

Licensing Agreements 11

Lipocine Enters into Licensing Agreement with Spriaso 11

Equity Offering 12

Lipocine to Raise USD20 Million in Public Offering of Shares 12

Lipocine Raises USD34.8 Million in Public Offering of Common Stock 13

Lipocine Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For USD14.2 Million 15

Lipocine Completes Private Placement Of Shares For USD37.8 Million 16

Lipocine Inc-Key Competitors 17

Lipocine Inc-Key Employees 18

Lipocine Inc-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Financial Announcements 20

Aug 07, 2017: Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017 20

May 08, 2017: Lipocine Announces Financial and Operational Results for the First Quarter 2017 22

Mar 06, 2017: Lipocine Announces Financial and Operational Results for the Full Year of 2016 23

Nov 08, 2016: Lipocine Announces Financial and Operational Results for the Third Quarter of 2016 24

Aug 09, 2016: Lipocine Announces Financial and Operational Results for the Second Quarter of 2016 25

May 09, 2016: Lipocine Announces Financial and Operational Results for the First Quarter of 2016 26

Mar 10, 2016: Lipocine Announces Financial and Operational Results for the Full Year of 2015 27

Corporate Communications 28

Feb 15, 2017: Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer 28

Legal and Regulatory 29

May 16, 2016: Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma and Lipocine 29

Product News 30

05/02/2016: Lipocine Announces the Presentation of Clinical Data for Oral Testosterone Replacement Therapy Product Candidate TLANDO ("LPCN 1021") at the 2016 American Urological Association Annual Meeting 30

03/28/2016: Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at the American Society of Andrology 41st Annual Conference 31

Clinical Trials 32

Mar 28, 2016: Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at ENDO 2016 32

Jan 04, 2016: Lipocine Announces First Patient Dosed in Phase 2B Clinical Study for LPCN 1111, a Novel Testosterone Replacement Therapy 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34

List of Figures

Lipocine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Lipocine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Lipocine Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Lipocine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Lipocine Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Lipocine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Marathon Bar And Lipocine Complete Reverse Merger Transaction 11

Lipocine Enters into Licensing Agreement with Spriaso 12

Lipocine to Raise USD20 Million in Public Offering of Shares 13

Lipocine Raises USD34.8 Million in Public Offering of Common Stock 14

Lipocine Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For USD14.2 Million 16

Lipocine Completes Private Placement Of Shares For USD37.8 Million 17

Lipocine Inc, Key Competitors 18

Lipocine Inc, Key Employees 19

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Lipocine Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16020
Site License
USD 500 INR 32040
Corporate User License
USD 750 INR 48060

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com